κανονισμοι covid-19: για εισοδο στην κλινικη ο επισκεπτης πρεπει να κατεχει εγκυρο pcr/rapid ή εμβολιο. Χρηση μασκας υποχρεωτικη.

info@scalamed.coμ+357 24 505600

covid-19 regulations: to enter the clinic visitor must hold a valid pcr / rapid or vaccine    covid-19 regulations: to enter the clinic visitor must hold a valid pcr / rapid or vaccine    covid-19 regulations: to enter the clinic visitor must hold a valid pcr / rapid or vaccine    covid-19 regulations: to enter the clinic visitor must hold a valid pcr / rapid or vaccine    covid-19 regulations: to enter the clinic visitor must hold a valid pcr / rapid or vaccine

ζητηστε ραντεβου
Close Button

Ελάτε σε επαφή με το κέντρο για να κλείσετε το ραντεβού σας. Με την υποβολή της φόρμας, μέλος από την ομάδα μας θα έρθει σε επαφή μαζί σας για την διευθέτηση του ραντεβού σας.

Thank you! Your submission has been received. A member of our clinic will contact you briefly.
*Oops! Something went wrong while submitting the form. Please try again.

Πολιτικη Απορρητου

Middle Subtitle

The Main Autoimmune Comorbidity Detected In 11 SLE Patients (16.67%) Was Antiphospholipid Syndrome (APS). This Was Followed By Immune Ombocytopenic Purpura And. The Main Autoimmune Comorbidity Detected In 11 SLE Patients (16.67%) Was Antiphospholipid Syndrome (APS). This Was Followed By Immune Ombocytopenic Purpura And. The Main Autoimmune Comorbidity Detected In 11 SLE Patients (16.67%) Was Antiphospholipid Syndrome (APS). This Was Followed By Immune Ombocytopenic Purpura And. The Main Autoimmune Comorbidity Detected In 11 SLE Patients (16.67%) Was Antiphospholipid Syndrome (APS). This Was Followed By Immune Ombocytopenic Purpura And.

Middle Subtitle

The Main Autoimmune Comorbidity Detected In 11 SLE Patients (16.67%) Was Antiphospholipid Syndrome (APS). This Was Followed By Immune Ombocytopenic Purpura And. The Main Autoimmune Comorbidity Detected In 11 SLE Patients (16.67%) Was Antiphospholipid Syndrome (APS). This Was Followed By Immune Ombocytopenic Purpura And. The Main Autoimmune Comorbidity Detected In 11 SLE Patients (16.67%) Was Antiphospholipid Syndrome (APS). This Was Followed By Immune Ombocytopenic Purpura And. The Main Autoimmune Comorbidity Detected In 11 SLE Patients (16.67%) Was Antiphospholipid Syndrome (APS). This Was Followed By Immune Ombocytopenic Purpura And.

Middle Subtitle

The Main Autoimmune Comorbidity Detected In 11 SLE Patients (16.67%) Was Antiphospholipid Syndrome (APS). This Was Followed By Immune Ombocytopenic Purpura And. The Main Autoimmune Comorbidity Detected In 11 SLE Patients (16.67%) Was Antiphospholipid Syndrome (APS). This Was Followed By Immune Ombocytopenic Purpura And. The Main Autoimmune Comorbidity Detected In 11 SLE Patients (16.67%) Was Antiphospholipid Syndrome (APS). This Was Followed By Immune Ombocytopenic Purpura And. The Main Autoimmune Comorbidity Detected In 11 SLE Patients (16.67%) Was Antiphospholipid Syndrome (APS). This Was Followed By Immune Ombocytopenic Purpura And.

Middle Subtitle

The Main Autoimmune Comorbidity Detected In 11 SLE Patients (16.67%) Was Antiphospholipid Syndrome (APS). This Was Followed By Immune Ombocytopenic Purpura And. The Main Autoimmune Comorbidity Detected In 11 SLE Patients (16.67%) Was Antiphospholipid Syndrome (APS). This Was Followed By Immune Ombocytopenic Purpura And. The Main Autoimmune Comorbidity Detected In 11 SLE Patients (16.67%) Was Antiphospholipid Syndrome (APS). This Was Followed By Immune Ombocytopenic Purpura And. The Main Autoimmune Comorbidity Detected In 11 SLE Patients (16.67%) Was Antiphospholipid Syndrome (APS). This Was Followed By Immune Ombocytopenic Purpura And.

Middle Subtitle

The Main Autoimmune Comorbidity Detected In 11 SLE Patients (16.67%) Was Antiphospholipid Syndrome (APS). This Was Followed By Immune Ombocytopenic Purpura And. The Main Autoimmune Comorbidity Detected In 11 SLE Patients (16.67%) Was Antiphospholipid Syndrome (APS). This Was Followed By Immune Ombocytopenic Purpura And. The Main Autoimmune Comorbidity Detected In 11 SLE Patients (16.67%) Was Antiphospholipid Syndrome (APS). This Was Followed By Immune Ombocytopenic Purpura And. The Main Autoimmune Comorbidity Detected In 11 SLE Patients (16.67%) Was Antiphospholipid Syndrome (APS). This Was Followed By Immune Ombocytopenic Purpura And.

Middle Subtitle

The Main Autoimmune Comorbidity Detected In 11 SLE Patients (16.67%) Was Antiphospholipid Syndrome (APS). This Was Followed By Immune Ombocytopenic Purpura And. The Main Autoimmune Comorbidity Detected In 11 SLE Patients (16.67%) Was Antiphospholipid Syndrome (APS). This Was Followed By Immune Ombocytopenic Purpura And. The Main Autoimmune Comorbidity Detected In 11 SLE Patients (16.67%) Was Antiphospholipid Syndrome (APS). This Was Followed By Immune Ombocytopenic Purpura And. The Main Autoimmune Comorbidity Detected In 11 SLE Patients (16.67%) Was Antiphospholipid Syndrome (APS). This Was Followed By Immune Ombocytopenic Purpura And.

SCALAMED

Ζητήστε Ραντεβού

Ζητηστε Ραντεβου
επικοινωνια
Νίκου Δημητρίου 36, 6031 Λάρνακα, Κύπρος.contact@scalamed.com+357 24 505600
προγραμμα
Δευτ.-Παρ.:
08:00 - 18:00
Σάββατο:
ΚΛΕΙΣΤΟ
Κυριακή:
ΚΛΕΙΣΤΟ
SOCIAL MEDIA
FacebookLinkedInTwitter
Copyright © 2022 Scalamed
|Designed by Nekativ
|Developed by Div&Tonic
Όροι και ΠροϋποθέσειςΠολιτική Απορρήτου